Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haleon plc (HLN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on both the London Stock Exchange and the New York Stock Exchange. Haleon files annual reports on Form 20-F and submits current reports on Form 6-K under the Securities Exchange Act of 1934. These filings cover topics such as trading statements, total voting rights and capital, board and committee changes, and transactions by persons discharging managerial responsibilities (PDMRs).
Recent 6-K filings include announcements on Haleon’s Q3 trading statement, regular updates on total voting rights and capital, and detailed notifications of share transactions under the company’s share reward plans by senior managers. Other filings describe governance developments, such as the appointment of a new Chair, changes to the Senior Independent Director role and committee memberships, and the evolution of Haleon’s operating model, including the creation of six Operating Units and new executive roles like Chief Growth Officer and Chief Transformation Officer.
Many filings contain an "About Haleon" section that reiterates the company’s profile as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other, along with examples of long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
On this page, investors can review Haleon’s SEC submissions as they are made available from EDGAR, while AI-powered tools on the platform can help summarise key points, highlight changes over time and surface information on areas such as capital structure, insider share dealings disclosed as PDMR transactions, and updates to the company’s governance and operating model.
On 05 Aug 2025, Haleon plc (HLN) filed a Form 6-K confirming execution of the second tranche of its share-buyback programme announced 31 Jul 2025. On 04 Aug 2025 the company repurchased 1,418,324 ordinary shares on the London Stock Exchange for cancellation. Purchase prices ranged from 355.90p to 364.60p, with a volume-weighted average of 358.534p. After settlement, issued share capital stands at 8,984,952,236 shares of £0.01 each; 3,880,205 shares are held in treasury, leaving 8,981,072,031 shares entitled to vote. A detailed trade log is available via the LSE RNS link and on Haleon’s investor site. No additional financial results or forward guidance were provided.
Haleon plc (HLN) Form 6-K: The company reports the purchase and cancellation of 1,281,000 ordinary shares (£0.01 par) on 1 Aug 2025, executed on the London Stock Exchange as part of the second tranche of its share-buyback programme announced 31 Jul 2025.
- Pricing: highest 368.4000p, lowest 359.0000p, volume-weighted average 364.8941p.
- The repurchase equals roughly 0.014% of the 8.98 bn shares outstanding.
- Post-settlement share capital totals 8,986,370,560, of which 3,880,205 are treasury shares, leaving 8,982,490,355 shares with voting rights.
The updated voting share count should be used for FCA disclosure thresholds. A trade-by-trade breakdown is available via the linked RNS PDF and on Haleon’s investor website. No additional financial or operational disclosures accompany this filing.
On 11 July 2025, Haleon plc (LSE/NYSE: HLN) disclosed a TR-1 major shareholding notification from Wellington Management Group LLP. The investment manager’s aggregated interest fell from 5.87 % to 5.29 % of Haleon’s voting rights as of 10 July 2025, comprising 4.97 % held directly through ordinary shares (446.9 m votes) and 0.32 % via financial instruments (predominantly depository receipts and small equity swaps). The absolute position equals 475.6 m voting rights.
The reduction keeps Wellington above the critical UK 5 % disclosure threshold but signals incremental selling. No operational or earnings data are included; the filing is purely ownership-related.
FAQ
What is the current stock price of Haleon (HLN)?
What is the market cap of Haleon (HLN)?
